Terms: = Endocrine gland cancer AND CARS, P49589, 833, ENSG00000110619 AND Treatment
64 results:
1. Chimeric Antigen Receptor T Cell Therapy for Pancreatic cancer: A Review of Current Evidence.
Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
[TBL] [Abstract] [Full Text] [Related]
2. Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
3. The diagnostic value of ultrasound on different-sized thyroid nodules based on ACR TI-RADS.
Li W; Chen J; Ye F; Xu D; Fan X; Yang C
Endocrine; 2023 Dec; 82(3):569-579. PubMed ID: 37656349
[TBL] [Abstract] [Full Text] [Related]
4. Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma.
Deza S; Maroto J; Tellechea O; Orbegozo N; Merino J; Galofré JC; Alegre E; González Á
Clin Chim Acta; 2023 Aug; 548():117502. PubMed ID: 37516333
[TBL] [Abstract] [Full Text] [Related]
5. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
[TBL] [Abstract] [Full Text] [Related]
7. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Reni M; Giommoni E; Bergamo F; Milella M; Cavanna L; Di Marco MC; Spada M; Cordio S; Aprile G; Cardellino GG; Maiello E; Bernardini I; Ghidini M; Bozzarelli S; Macchini M; Orsi G; De Simone I; Rulli E; Porcu L; Torri V; Pinto C;
ESMO Open; 2023 Feb; 8(1):100777. PubMed ID: 36731325
[TBL] [Abstract] [Full Text] [Related]
8. [Association of extranodal extension and lymph node ratio with radioactive iodine-refractory papillary thyroid cancer].
Luo ZY; Qin JW; Fang JG; Zheng C; Gong WB; Hei H
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3856-3861. PubMed ID: 36540923
[No Abstract] [Full Text] [Related]
9. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
10. Establishment of the diagnostic and prognostic nomograms for pancreatic cancer with bone metastasis.
Liu Z; Liu H; Wang D
Sci Rep; 2022 Oct; 12(1):18085. PubMed ID: 36302941
[TBL] [Abstract] [Full Text] [Related]
11. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan.
Kubota S; Haraguchi T; Kuwata H; Seino Y; Murotani K; Tajima T; Terashima G; Kaneko M; Takahashi Y; Takao K; Kato T; Shide K; Imai S; Suzuki A; Terauchi Y; Yamada Y; Seino Y; Yabe D
J Diabetes Investig; 2023 Jan; 14(1):67-74. PubMed ID: 36281720
[TBL] [Abstract] [Full Text] [Related]
12. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
[TBL] [Abstract] [Full Text] [Related]
13. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).
Brugel M; Letrillart L; Evrard C; Thierry A; Tougeron D; El Amrani M; Piessen G; Truant S; Turpin A; d'Engremont C; Roth G; Hautefeuille V; Regimbeau JM; Williet N; Schwarz L; Di Fiore F; Borg C; Doussot A; Lambert A; Moulin V; Trelohan H; Bolliet M; Topolscki A; Ayav A; Lopez A; Botsen D; Piardi T; Carlier C; Bouché O
Eur J Cancer; 2022 May; 166():8-20. PubMed ID: 35259629
[TBL] [Abstract] [Full Text] [Related]
14. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.
Barrak D; Villano AM; Villafane-Ferriol N; Stockton LG; Hill MV; Deng M; Handorf EA; Reddy SS
Eur J Surg Oncol; 2022 Jun; 48(6):1356-1361. PubMed ID: 35016837
[TBL] [Abstract] [Full Text] [Related]
15. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
16. A novel staging system and clinical predictive nomogram for more accurate staging and prognosis of malignant pancreatic intraductal papillary mucinous neoplasms: a population-based study.
Zhang H; Gao C; Chen J; Wu S; Bai J; Yin T
J Transl Med; 2021 Dec; 19(1):525. PubMed ID: 34952605
[TBL] [Abstract] [Full Text] [Related]
17. Distal pancreatectomy with resection of the celiac trunk, right or left hepatic artery without arterial reconstruction (extended DP-CAR).
Egorov VI; Petrov RV; Amosova EL; Kharazov AF; Petrov KS; Zhurina YA; Kondratyev EV; Zelter PM; Dzigasov SO; Grigorievsky MV
Khirurgiia (Mosk); 2021; (10):13-28. PubMed ID: 34608776
[TBL] [Abstract] [Full Text] [Related]
18. Chimeric Antigen Receptor Design and Efficacy in Ovarian cancer treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract] [Full Text] [Related]
19. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic cancer.
Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
[TBL] [Abstract] [Full Text] [Related]
20. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment.
Lee YE; Ju A; Choi HW; Kim JC; Kim EE; Kim TS; Kang HJ; Kim SY; Jang JY; Ku JL; Kim SC; Jun E; Jang M
J Control Release; 2020 Oct; 326():310-323. PubMed ID: 32682905
[TBL] [Abstract] [Full Text] [Related]
[Next]
